I-Mab Biopharma has signed an agreement to divest its assets and business operations in China, becoming a US-based biotech company. The divesting will provide I-Mab with a healthy balance sheet, over ...

Needham has decided to maintain its Buy rating of I-MAB (NASDAQ:IMAB) and lower its price target from $72.00 to $41.00. Shares of I-MAB are trading down 15.43% over the last 24 hours, at $6.74 per ...

Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener I-MAB ( (IMAB)) has ...

I-Mab acquires Bridge Health, gaining upstream rights to CLDN18.2 antibody, reducing milestone payments for givastomig and eliminating royalties. I-Mab has announced its acquisition of Bridge Health ...

The long journey from cell culture to a purified monoclonal antibody (mAb) involves many sample processing steps, with clarification and filtration playing significant roles. However, clogs, complex ...

I-Mab (NASDAQ:IMAB) said on Thursday that it has signed an agreement to acquire Bridge Health Biotech. As part of the deal, I-Mab will provide an initial payment of $1.8M to Bridge Health shareholders ...

Chinese biotechnology firm I-Mab is weighing strategic options as it holds early talks with other global biopharmaceutical companies about partnerships and investments, according to people familiar ...